A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses

Journal of Clinical Virology

Volumn 65, Issue , 2015, Pages 32-37

  Kouiavskaia, Diana ^a   Chen, Zhaochun ^b   Dragunsky, Eugenia ^a   Mirochnitchenko, Olga ^a   Purcell, Robert ^b   Chumakov, Konstantin ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antiviral therapy; Chronic virus excretors; Drug resistance; Emergency prophylaxis; Polio eradication

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A12; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; FEMALE; HUMAN POLIOVIRUS 1; HUMAN POLIOVIRUS 2; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LETHAL DOSE; MALE; MOUSE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; VIRUS STRAIN; WILD TYPE; ANIMAL; ANTIVIRAL RESISTANCE; HUMAN; IMMUNOLOGY; PAN TROGLODYTES; POLIOMYELITIS; POLIOMYELITIS VIRUS; SERODIAGNOSIS; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; DRUG RESISTANCE, VIRAL; HUMANS; MICE; NEUTRALIZATION TESTS; PAN TROGLODYTES; POLIOMYELITIS; POLIOVIRUS; POST-EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; VACCINATION;

EID: 84924303127     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.01.023     Document Type: Article

References (24)

1. Hull H.F., Lee J.W. Sabin, Salk, or sequential?. Lancet 1996, 347:630. http://www.ncbi.nlm.nih.gov/pubmed/8596370.
2. Almond J.W. The attenuation of poliovirus neurovirulence. Annu. Rev. Microbiol. 1987, 41:153-180. 10.1146/annurev.mi.41.100187.001101.
3. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27:2649-2652. 10.1016/j.vaccine.2009.02.071.
4. M. Roivainen, S. Blomqvist, H. Al-Hello, A. Paananen , F. Delpeyroux , M. Kuusi , et al. Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage, Euro surveillance: bulletin Europeen sur les maladies transmissibles=European communicable disease bulletin, 2010, 15, pii/1956, . http://www.ncbi.nlm.nih.gov/pubmed/20483108.
5. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 2005, 59:587-635. 10.1146/annurev.micro.58.030603.123625.
6. Collett M.S., Neyts J., Modlin J.F. A case for developing antiviral drugs against polio. Antivir. Res. 2008, 79:179-187. 10.1016/j.antiviral.2008.04.002.
7. Chen Z., Chumakov K., Dragunsky E., Kouiavskaia D., Makiya M., Neverov A., et al. Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis. J. Virol. 2011, 85:4354-4362. 10.1128/JVI.2,553-10.
8. Koike S., Taya C., Kurata T., Abe S., Ise I., Yonekawa H., et al. Transgenic mice susceptible to poliovirus. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:951-955. http://www.ncbi.nlm.nih.gov/pubmed/1846972.
9. Blondel B., Crainic R., Fichot O., Dufraisse G., Candrea A., Diamond D., et al. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J. Virol. 1986, 57:81-90. http://www.ncbi.nlm.nih.gov/pubmed/2416957.
10. Kouiavskaia D.V., Dragunsky E.M., Liu H.M., Oberste M.S., Collett M.S., Chumakov K.M. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073. Antivir. Ther. 2011, 16:999-1004. 10.3851/IMP1838.
11. Liu H.M., Roberts J.A., Moore D., Anderson B., Pallansch M.A., Pevear D.C., et al. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. Antimicrob. Agents Chemother. 2012, 56:5568-5574. 10.1128/AAC.539-12.
12. WHO Manual for the Virological Investigation of Polio 1997, WHO_EPI_GEN_9701, Geneva.
13. WHO Maintenance and distribution of transgenic mice susceptible to human viruses: memorandum from a WHO meeting. Bull. World Health Organ. 1993, 71:497-502.
14. NRC Guide for the Care and Use of Laboratory Animals 2011, The National Academies Press. Eighth ed.
15. Deng R., Loyet K.M., Lien S., Iyer S., DeForge L.E., Theil F.P., et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab. Dispos. 2010, 38:600-605. 10.1124/dmd.109.031310.
16. Milenic D.E., Wong K.J., Baidoo K.E., Ray G.L., Garmestani K., Williams M., et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer biother. Radiopharm. 2008, 23:619-631. 10.1089/cbr.2008.0493.
17. WHO Neurovirulence Test of Types 1, 2, or 3 Live Attenuated Poliomyelitis Vaccines (oral) in Transgenic Mice Susceptible to Poliovirus 2012, SOP, Version 6.
18. MacLennan C., Dunn G., Huissoon A.P., Kumararatne D.S., Martin J., O'Leary P., et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 2004, 363:1509-1513. 10.1016/S0140-6736(04)16,150-3.
19. Pfeiffer J.K., Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7289-7294. 10.1073/pnas.1232294100.
20. Committee on development of a polio antiviral and its potential role in global poliomyelitis eradication N Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report 2006, The National Academies Press, Washington, DC.
21. Hammon W.M., Coriell L.I., Stokes J. Evaluation of red cross gamma globulin as a prophylactic agent for poliomyelitis. J. Am. Med. Assoc. 1952, 150:139.
22. Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev. Biol. 2001, 105:75-80. http://www.ncbi.nlm.nih.gov/pubmed/11763340.
23. de Silva R., Gunasena S., Ratnayake D., Wickremesinghe G.D., Kumarasiri C.D., Pushpakumara B.A., et al. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine 2012, 30:7561-7565. 10.1016/j.vaccine.2012.10.035.
24. Puligedda R.D., Kouiavskaia D., Adekar S.P., Sharma R., Devi Kattala C., Rezapkin G., et al. Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains. Antivir. Res. 2014, 108:36-43. 10.1016/j.antiviral.2014.05.005.